Wockhardt Ltd

WOCKPHARMA

Company Profile

  • Business description

    Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.

  • Contact

    Bandra-Kurla Complex
    Wockhardt Towers
    Bandra East
    MumbaiMH400051
    IND

    T: +91 2226534444

    https://www.wockhardt.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    2,296

Stocks News & Analysis

stocks

ASX tech share tracking below guidance

Moat Rating downgraded for overvalued shares.
stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,717.0082.40-0.94%
CAC 408,047.9166.150.83%
DAX 4024,527.53126.880.52%
Dow JONES (US)49,382.8618.980.04%
FTSE 10010,374.2843.730.42%
HKSE25,651.12146.73-0.57%
NASDAQ26,038.88168.170.65%
Nikkei 22559,804.41746.18-1.23%
NZX 50 Index12,761.03213.29-1.64%
S&P 5007,381.3227.710.38%
S&P/ASX 2008,496.6076.50-0.89%
SSE Composite Index4,162.187.35-0.18%

Market Movers